Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) CEO Chad Robins sold 278,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $24.48, for a total value of $6,821,988.48. Following the sale, the chief executive officer directly owned 2,180,518 shares of the company’s stock, valued at $53,379,080.64. This represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Adaptive Biotechnologies Stock Performance
Shares of Adaptive Biotechnologies stock opened at $25.99 on Friday. The stock’s fifty day moving average is $22.06 and its two-hundred day moving average is $17.35. The company has a market capitalization of $4.15 billion, a PE ratio of -63.39 and a beta of 2.08. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.16.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) earnings per share. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on ADPT
Hedge Funds Weigh In On Adaptive Biotechnologies
Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC grew its holdings in Adaptive Biotechnologies by 45.8% during the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies during the first quarter valued at approximately $93,000. New York State Common Retirement Fund boosted its stake in shares of Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Adaptive Biotechnologies by 728.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after buying an additional 333,379 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
- Five stocks we like better than Adaptive Biotechnologies
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
